Diffregen is a startup focused on development of new leukemia drug candidates.  Our active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells.

 

Graphic attribution: Medical gallery of Blausen Medical 2014. WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436.

Leave a Reply

Your email address will not be published. Required fields are marked *